PMID- 38192918
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240110
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 15
IP  - 12
DP  - 2023 Dec
TI  - The Influence of Coffee on Reducing Metabolic Dysfunction-Associated Steatotic 
      Liver Disease in Patients With Type 2 Diabetes: A Review.
PG  - e50118
LID - 10.7759/cureus.50118 [doi]
LID - e50118
AB  - Metabolic dysfunction-associated steatotic liver disease (MASLD) is a liver 
      disease characterized by hepatic fat accumulation associated with various 
      severities of inflammation and scarring. As studies explore specialized 
      treatments, emerging evidence suggests a potential protective effect of coffee 
      consumption. Consumption of coffee or its components, such as caffeine and/or 
      chlorogenic acid (CA), can reduce markers of liver injury and induce a myriad of 
      other health benefits. However, there is limited research on patients with both 
      MASLD and type 2 diabetes (T2D). Current research suggests that patients with 
      MASLD are at greater risk of developing T2D and future liver-related 
      complications and vice versa. Given that both MASLD and T2D are global burdens, 
      the present literature review analyzes current research to identify trends and 
      determine if coffee can be a viable treatment for MASLD patients with T2D. 
      Results indicate that coffee consumption may protect against MASLD in T2D 
      patients who are overweight/obese through a declined rate of weight gain, 
      inhibition of the mammalian target of rapamycin (mTOR) gene, and insignificant 
      changes to the gut microbiome. More longitudinal research on human subjects is 
      needed to establish a causal relationship between coffee consumption and MASLD 
      alleviation.
CI  - Copyright (c) 2023, Kaur et al.
FAU - Kaur, Manpreet
AU  - Kaur M
AD  - Medicine, University of California, Davis, Davis, USA.
FAU - Murugesan, Shanmathi
AU  - Murugesan S
AD  - Medicine, University of California, Davis, Davis, USA.
FAU - Singh, Sachpreet
AU  - Singh S
AD  - Information Technology, Florin High School, Sacramento, USA.
FAU - Uy, Katherine N
AU  - Uy KN
AD  - Medicine, University of California, Davis, Davis, USA.
FAU - Kaur, Jasjeet
AU  - Kaur J
AD  - Medicine, University of California, Davis, Davis, USA.
FAU - Mann, Navina
AU  - Mann N
AD  - Medicine, University of California, Davis, Davis, USA.
FAU - Sekhon, Rajneet K
AU  - Sekhon RK
AD  - Geriatrics, Rajneet K Sekhon MD Inc., Folsom, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231207
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10772480
OTO - NOTNLM
OT  - caffeine intake
OT  - chlorogenic acid
OT  - fatty liver disease
OT  - hepatic autophagy
OT  - obesity and overweight
OT  - type 2 diabetes
COIS- The authors have declared that no competing interests exist.
EDAT- 2024/01/09 06:41
MHDA- 2024/01/09 06:42
PMCR- 2023/12/07
CRDT- 2024/01/09 03:58
PHST- 2023/12/07 00:00 [accepted]
PHST- 2024/01/09 06:42 [medline]
PHST- 2024/01/09 06:41 [pubmed]
PHST- 2024/01/09 03:58 [entrez]
PHST- 2023/12/07 00:00 [pmc-release]
AID - 10.7759/cureus.50118 [doi]
PST - epublish
SO  - Cureus. 2023 Dec 7;15(12):e50118. doi: 10.7759/cureus.50118. eCollection 2023 
      Dec.